BLSM · XBRL financial data

BlossomHill Therapeutics financial statements, every quarter

The same tables from 1 filing, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters

In thousands of dollars	Q2 FY26Jun 30, 2026
Research and development	21,355
General and administrative	3,315
Total operating expenses	24,670
Operating income (loss)	(24,670)
Other income (expense)	912
Net income (loss)	(23,758)
Earnings per share, basic USD per share	(8.75)
Earnings per share, diluted USD per share	(8.75)
Weighted average shares, basic thousands of shares	2,714
Weighted average shares, diluted thousands of shares	2,714

Fiscal quarters

In thousands of dollars	Q2 FY26Jun 30, 2026
Cash and cash equivalents	95,376
Prepaid and other current assets	5,592
Total current assets	100,968
Property and equipment, net	1,489
Right-of-use asset	19,197
Total assets	124,131
Accounts payable	3,930
Accrued liabilities	3,539
Total current liabilities	18,621
Lease liability, non-current	22,222
Total liabilities	42,088
Accumulated deficit	(179,795)
Total stockholders' equity	(174,780)
Total liabilities and equity	124,131
Common shares outstanding (cover page) thousands of shares	31,785

Fiscal quarters

In thousands of dollars	Q2 FY26Jun 30, 2026
Net income (loss)	(23,758)

The peer list for this company is being put together from its industry's latest filings. Reload the page in a minute to see it.

Not investment advice. Not affiliated with the U.S. SEC.